⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11630439 | 0.97 | — | — | |
| SCHEMBL3065037 | 0.74 | — | — | |
| SCHEMBL3649966 | 0.73 | — | — | |
| SCHEMBL756107 | 0.73 | — | — | |
| SCHEMBL764245 | 0.71 | — | — | |
| SCHEMBL6972596 | 0.71 | — | — | |
| SCHEMBL2216660 | 0.71 | — | — | |
| SCHEMBL3771818 | 0.69 | TSHR (0.39) | — | |
| SCHEMBL5906377 | 0.69 | — | — | |
| SCHEMBL5660160 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1795197-B | Cephem compound | DSM IP ASSETS BV | 2010-06-02 | — | — | CN | claimed |
| CN-1795197-A | Cephem compound | DSM IP ASSETS BV (NL) | 2006-06-28 | — | — | CN | claimed |
| CN-116801884-B | Combination therapy for HIV using adenosine derivatives and capsid inhibitors | 腾盛博药生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4601648-A2 | ACRIDINIUM COMPOUNDS WITH FUSED HETEROCYCLES | Siemens Healthcare Diagnostics Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-120035441-A | Acridinium compounds having fused heterocycles | 美国西门子医学诊断股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025096599-A1 | MEASUREMENT OF MULTIPLE ANALYTES USING ACRIDINIUM LABELS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119823106-A | Enhanced nucleic acid polymerization by aromatic compounds | 豪夫迈·罗氏有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-114502175-B | Adenosine derivatives and pharmaceutical compositions containing the same | 腾盛博药生物科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114144520-B | Enhanced nucleic acid polymerization by aromatic compounds | 豪夫迈·罗氏有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024081561-A2 | ACRIDINIUM COMPOUNDS WITH FUSED HETEROCYCLES | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-116801884-A | Combination therapy for HIV using adenosine derivatives and capsid inhibitors | 腾盛博药生物科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-5126258-A | Hydrolysis of polypeptides at predetermined site | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-06-30 | — | — | US | disclosed |
| EP-0454766-A4 | POLYVALENT METAL ION-CONTAINING ANTIBODY COMBINING SITE CATALYSTS | — | 1991-12-04 | — | — | EP | disclosed |
| EP-0454766-A1 | Polyvalent metal ion-containing antibody combining site catalysts | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-11-06 | — | — | EP | disclosed |
| EP-0454778-A1 | MOLECULES WITH ANTIBODY COMBINING SITES THAT EXHIBIT STEREOSPECIFIC CATALYSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1991-11-06 | — | — | EP | disclosed |
| WO-1991005804-A1 | CATALYSIS OF DIELS-ALDER REACTIONS, METHODS AND CATALYSTS THEREFOR | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-05-02 | — | — | WO | disclosed |
| WO-1990008185-A1 | MOLECULES WITH ANTIBODY COMBINING SITES THAT EXHIBIT STEREOSPECIFIC CATALYSIS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-07-26 | — | — | WO | disclosed |
| WO-1990007934-A1 | POLYVALENT METAL ION-CONTAINING ANTIBODY COMBINING SITE CATALYSTS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-07-26 | — | — | WO | disclosed |
| US-4085202-A | Testosterone derivatives | BECTON, DICKINSON AND COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |